Determination of Blood Loss After CS

Early Phase 1UnknownNCT04549012

Ain Shams University130 enrolled

Overview

Comparing betweeen tranexamic acid plus oxytocin and oxytocin alone in their efficacy in reducing blood loss following CS

tranexamic acid plus oxytocin versus oxytocin only in reducing blood loss following CS

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Enrollment

130

Conditions

Effect of Drug

Interventions

Tranexamic acidDRUG

comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS

OxytocinDRUG

Oxytocin

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age : 20-40 year * 2- Gestational age is between 37-41weeks 3- Delivery by uncomplicated elective CS Exclusion Criteria: * 1- Risk factors for uterine atony such as polyhydramnios or fetal macrosomia. 2- Grandmultiparity 3- Past history of postpartum hemorrhage either atonic or traumatic 4- Previous history of retained placenta 5- Pre-eclampsia or gestational hypertension/ Maternal DM 6- Abnormal placentation 7- Contraindications to the use of tranexamic acid 8- Hypersensitivity to tranexamic acid. 9- Women receiving anticoagulant therapy. 10- having underlying disease (heart, liver, kidney, pulmonary, etc.),

Outcomes

Primary Outcomes

amount of blood loss

comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS

Time frame: baseline

Secondary Outcomes

maternal and neonatal complication

blood transfusion ,surgical injuries ,

Time frame: baseline

Central Contacts

noha abu shata

CONTACT

01000287839 mhmwdnhy44@gmail.com

tamer Borg

CONTACT

01001457437 tamerborg1975@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.